|
mutLBSgeneDB |
| |
| |
| |
| |
| |
| |
|
| Gene summary for PARP3 |
 Gene summary |
| Basic gene Info. | Gene symbol | PARP3 |
| Gene name | poly (ADP-ribose) polymerase family, member 3 | |
| Synonyms | ADPRT3|ADPRTL2|ADPRTL3|ARTD3|IRT1|PADPRT-3 | |
| Cytomap | UCSC genome browser: 3p21.31-p21.1 | |
| Type of gene | protein-coding | |
| RefGenes | NM_001003931.3, NM_005485.5,NM_001003935.2, | |
| Description | ADP-ribosyltransferase (NAD+; poly (ADP-ribose) polymerase)-like 2ADP-ribosyltransferase (NAD+; poly (ADP-ribose) polymerase)-like 3ADP-ribosyltransferase diphtheria toxin-like 3ADPRT-3NAD(+) ADP-ribosyltransferase 3NAD+ ADP-ribosyltransferase 3poly | |
| Modification date | 20141207 | |
| dbXrefs | MIM : 607726 | |
| HGNC : HGNC | ||
| Ensembl : ENSG00000041880 | ||
| HPRD : 06370 | ||
| Vega : OTTHUMG00000156931 | ||
| Protein | UniProt: Q9Y6F1 go to UniProt's Cross Reference DB Table | |
| Expression | CleanEX: HS_PARP3 | |
| BioGPS: 10039 | ||
| Pathway | NCI Pathway Interaction Database: PARP3 | |
| KEGG: PARP3 | ||
| REACTOME: PARP3 | ||
| Pathway Commons: PARP3 | ||
| Context | iHOP: PARP3 | |
| ligand binding site mutation search in PubMed: PARP3 | ||
| UCL Cancer Institute: PARP3 | ||
| Assigned class in mutLBSgeneDB | B: This gene belongs to targetable_mutLBSgenes. | |
| Gene ontology having evidence of Inferred from Direct Assay (IDA) from Entrez |
| GO ID | GO Term | PubMed ID | GO:0006302 | double-strand break repair | 21270334 | GO:0006471 | protein ADP-ribosylation | 21270334 |
| Top |
| Ligand binding site mutations for PARP3 |
| Lollipop-style diagram of mutations at LBS in amino-acid sequence. We represented ligand binding site mutations only. (You can see big image via clicking.)  : non-synonymous mutation on LBS, Circle size denotes number of samples. |
 |
| Cancer type specific mutLBS sorted by frequency |
| LBS | AAchange of nsSNV | Cancer type | # samples | A416 | E418D | UCEC | 1 | V288 | L289M | UCEC | 1 |
| cf) Cancer type abbreviation. BLCA: Bladder urothelial carcinoma, BRCA: Breast invasive carcinoma, CESC: Cervical squamous cell carcinoma and endocervical adenocarcinoma, COAD: Colon adenocarcinoma, GBM: Glioblastoma multiforme, LGG: Brain lower grade glioma, HNSC: Head and neck squamous cell carcinoma, KICH: Kidney chromophobe, KIRC: Kidney renal clear cell carcinoma, KIRP: Kidney renal papillary cell carcinoma, LAML: Acute myeloid leukemia, LUAD: Lung adenocarcinoma, LUSC: Lung squamous cell carcinoma, OV: Ovarian serous cystadenocarcinoma, PAAD: Pancreatic adenocarcinoma, PRAD: Prostate adenocarcinoma, SKCM: Skin cutaneous melanoma, STAD: Stomach adenocarcinoma, THCA: Thyroid carcinoma, UCEC: Uterine corpus endometrial carcinoma. |
| Top |
| Protein structure related information for PARP3 |
| Relative protein structure stability change (ΔΔE) using Mupro 1.1 Mupro score denotes assessment of the effect of mutations on thermodynamic stability. (ΔΔE<0: mutation decreases stability, ΔΔE>0: mutation increases stability) |
 : nsSNV at non-LBS : nsSNV at LBS |
 |
| nsSNVs sorted by the relative stability change of protein structure by each mutation Blue: mutations of positive stability change. and red : the most recurrent mutation for this gene. |
| LBS | AAchange of nsSNV | Relative stability change | V288 | L289M | -1.0065807 | A416 | E418D | -0.20541743 |
| (MuPro1.1: Jianlin Cheng et al., Prediction of Protein Stability Changes for Single-Site Mutations Using Support Vector Machines, PROTEINS: Structure, Function, and Bioinformatics. 2006, 62:1125-1132) |
| Structure image for PARP3 from PDB |
| Top |
| Differential gene expression and gene-gene network for PARP3 |
| Differential gene expression between mutated and non-mutated LBS samples in all 16 major cancer types |
| Differential co-expressed gene network based on protein-protein interaction data (CePIN) |
| Top |
| Top |
| Phenotype information for PARP3 |
| Gene level disease information (DisGeNet) |
| Disease ID | Disease name | # PubMed | Association type |
| Mutation level pathogenic information (ClinVar annotation) |
| Allele ID | AA change | Clinical significance | Origin | Phenotype IDs |
| Top |
| Pharmacological information for PARP3 |
| Gene expression profile of anticancer drug treated cell-lines (CCLE) Heatmap showing the correlation between gene expression and drug response across all the cell-lines. We chose the top 20 among 138 drugs.We used Pearson's correlation coefficient. |
 |
| Gene-centered drug-gene interaction network |
 |
| Drug information targeting mutLBSgene (Approved drugs only) |
| Drug status | DrugBank ID | Name | Type | Drug structure |
| Experimental | DB07677 | 2-methyl-3,5,7,8-tetrahydro-4H-thiopyrano[4,3-d]pyrimidin-4-one | Small molecule |  |
| Experimental | DB08058 | 4-[3-(1,4-diazepan-1-ylcarbonyl)-4-fluorobenzyl]phthalazin-1(2H)-one | Small molecule |  |
| Experimental | DB08348 | N~2~,N~2~-DIMETHYL-N~1~-(6-OXO-5,6-DIHYDROPHENANTHRIDIN-2-YL)GLYCINAMIDE | Small molecule |  |
| Approved | DB09074 | Olaparib | Small molecule |  |
| Gene-centered ligand-gene interaction network |
 |
| Ligands binding to mutated ligand binding site of PARP3 go to BioLip |
| Ligand ID | Ligand short name | Ligand long name | PDB ID | PDB name | mutLBS | P34 | N~2~,N~2~-DIMETHYL-N~1~-(6-OXO-5,6-DIHYDROPHENANTHRIDIN-2-YL)GLYCINAMIDE | 3ce0 | A | A416 | GAB | 3-AMINOBENZOIC ACID | 3fhb | A | A416 | 1DC | 3-(4-OXO-3,4-DIHYDROQUINAZOLIN-2-YL)-N-[(1S)-1- (PYRIDIN-4-YL)ETHYL]PROPANAMIDE | 4l6z | A | V288 | 1VD | N-{(1S)-1-[4-(1H-IMIDAZOL-1-YL)PHENYL]ETHYL}-3-(4-OXO- 3,4-DIHYDROQUINAZOLIN-2-YL)PROPANAMIDE | 4l7o | A | V288 | 1VC | METHYL N-[3-(4-OXO-3,4-DIHYDROQUINAZOLIN-2-YL) PROPANOYL]-L-PHENYLALANINATE | 4l7u | A | V288 A416 |
| Top |
| Conservation information for LBS of PARP3 |
| Multiple alignments for Q9Y6F1 in multiple species |
| LBS | AA sequence | # species | Species |
 |
Copyright © 2016-Present - The University of Texas Health Science Center at Houston |